| Ytd | 74.78% | |
| 1y | 221.14% |
| Open | 2.08 | Prev Close | 2.06 | Low | 1.96 | High | 2.08 | Mkt Cap | 265.76M |
| Vol | 221.17K | Avg Vol | 1.38M | EPS | -1.13 | P/E | -1.75 | Forward P/E | -0.68 |
| Beta | 0.42 | Short Ratio | 8.58 | Inst. Own | 88.21% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-08 | 50-d Avg | 1.89 | 200-d Avg | 1.77 | 1yr Est | 7.67 |
ALXO News
Here is how ALX Oncology Holdings Inc. (ALXO) and Medpace (MEDP) have performed compared to their se
– On track for mid-2027 topline data readout from 80 patients in the Phase 2 ASPEN-09-Breast clinica
SOUTH SAN FRANCISCO, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Onco
Strengthens Leadership with Veteran Executives with Decades of Industry Experience Scott Garland Suc
SOUTH SAN FRANCISCO, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Onco
Here is how ALX Oncology Holdings Inc. (ALXO) and Biodesix, Inc. (BDSX) have performed compared to t
ALX Oncology Holdings Inc. (ALXO) Q1 2026 Earnings Call Transcript
ALX Oncology NASDAQ: ALXO executives used the company's first-quarter 2026 earnings call to highligh
- Data from Phase 1b/2 trial of evorpaceptzanidatamab presented at ESMO Breast Cancer 2026 showed al
The Phase 1b/2 open-label, multi-center clinical trial (NCT05027139) evaluating evorpacept plus zani
- Data from Phase 1b/2 trial presented at ESMO Breast Cancer 2026 further validate a biomarker-drive
- Company Will Discuss Data and Report First Quarter 2026 Financial Results on May 8 - SOUTH SAN FRA
SOUTH SAN FRANCISCO, Calif., April 17, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Onc
- Veteran biopharmaceutical and oncology leader brings more than three decades of experience across
ALX Oncology Holdings Inc. (NASDAQ: ALXO - Get Free Report) saw a significant growth in short intere
ALX Oncology (NASDAQ: ALXO) outlined progress across its two core programs-CD47 blocker evorpacept a
ALX Oncology Holdings Inc. (ALXO) Q4 2025 Earnings Call Transcript
- Clinical development for both the investigational CD47-inhibitor evorpacept and the novel EGFR-tar
SOUTH SAN FRANCISCO, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Onco
SOUTH SAN FRANCISCO, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Onco
ALX Oncology Holdings Inc. ("ALX Oncology," Nasdaq: ALXO), a clinical-stage biotechnology co
On Monday, 76 companies set new 52-week lows.
On Monday, 198 companies hit new 52-week lows.
On Friday, 497 companies set new 52-week lows.
During Monday's trading, 1214 companies set new 52-week lows.
Monday's session saw 84 companies set new 52-week lows.
On Tuesday, 540 companies set new 52-week lows.
On Friday, 1043 companies hit new 52-week lows.
During Wednesday's trading, 435 companies set new 52-week lows.
Tuesday's session saw 211 companies set new 52-week lows.
During Thursday, 849 stocks hit new 52-week lows.
Gainers Clovis Oncology, Inc. (NASDAQ: CLVS) shares climbed 47.7% to close at $7.86 on Friday af